News
The Phase III clinical trial application for first-line treatment of extensive disease small cell lung cancer with Chiauranib has been approved
SHENZHEN, China, Nov. 1, 2024 /PRNewswire/ -- On November 1, Shenzhen Chipscreen Biosciences Co., Ltd. (hereinafter referred to as "Chipscreen Biosciences") and its wholly-owned subsidiary Chengdu Chipscreen Pharmaceutical Ltd., received the "Drug Cl
By: en_prnasisa
- Nov 01 2024
- 0
- 0 Views
ONLY AVAILABLE IN PAID PLANS